Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients

Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients

The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients > 28 kg/m² with various liver diseases in patients with chronic liver disease scheduled for a liver biopsy.

Inclusion Criteria:

• Patient of at least 18 years of age
• Patient able to give written informed consent form
• Patient with a BMI superior or equal to 28kg/m²
• Patient scheduled to have a liver biopsy within 1 month after the enrollment or with a liver biopsy performed within 6 months before the enrollment.
• Patient for which abdominal ultrasound is technically possible

Exclusion Criteria:

• Unable or unwilling to provide written informed consent
• Confirmed diagnosis and/or history of malignancy, or other terminal disease
• Patients with clinical ascites
• Pregnant women
• Patient with a BMI < 28 kg/m²
• Patients with any active implantable medical device (such as pacemaker or defibrillator)
• Transplanted patient and patient with heart disease
• Refusal to undergo a liver biopsy